Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CMPI

Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis

Checkmate Pharmaceuticals logo

About Checkmate Pharmaceuticals Stock (NASDAQ:CMPI)

Advanced Chart

Key Stats

Today's Range
$10.50
$10.50
50-Day Range
$10.37
$10.50
52-Week Range
$2.00
$10.50
Volume
N/A
Average Volume
142,261 shs
Market Capitalization
$231.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CMPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CMPI Stock News Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
See More Headlines

CMPI Stock Analysis - Frequently Asked Questions

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) announced its earnings results on Friday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.02.

Checkmate Pharmaceuticals (CMPI) raised $75 million in an initial public offering on Friday, August 7th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkmate Pharmaceuticals investors own include Athenex (ATNX), KLX Energy Services (KLXE), TherapeuticsMD (TXMD), BioNTech (BNTX), Bolt Biotherapeutics (BOLT), Nabors Industries (NBR) and NGL Energy Partners (NGL).

Company Calendar

Last Earnings
11/12/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPI
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.50 per share
Price / Book
4.20

Miscellaneous

Free Float
8,242,000
Market Cap
$231.40 million
Optionable
Not Optionable
Beta
-4.81
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CMPI) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners